Roivant Sciences Ltd. (NASDAQ: ROIV) reported Q2 EPS of ($0.40), $0.11 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $37.1 million versus the consensus estimate of $29.11 million.

For earnings history and earnings-related data on Roivant Sciences Ltd. (ROIV) click here.